Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + nifedipine is a fixed-dose combination drug, most commonly formulated as a topical ointment or cream, used primarily for the treatment of chronic anal fissures and related anorectal pain. Lidocaine is an amide-type local anesthetic that works by reversibly stabilizing neuronal membranes, thereby blocking the initiation and conduction of nerve impulses to provide local anesthesia. Nifedipine is a dihydropyridine calcium channel blocker that relaxes smooth muscle cells in blood vessels and the internal anal sphincter by inhibiting voltage-dependent calcium channels. This dual action results in rapid pain relief (from lidocaine) and reduced sphincter spasm with improved blood flow (from nifedipine), promoting healing of fissures. The combination has demonstrated high efficacy in clinical trials for healing chronic anal fissure, reducing resting anal pressure, relieving pain after hemorrhoidectomy, and improving patient comfort[1][4][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + nifedipine.